Gilead to build up independent Japan ops through new subsidiary
This article was originally published in Scrip
Executive Summary
Gilead Sciences has set up a new subsidiary in Japan that will focus initially on the local clinical development of sofosbuvir for hepatitis C virus (HCV) and over the longer term the independent commercialization of this and other pipeline products, including in oncology.